118 related articles for article (PubMed ID: 17592218)
1. Transdermal treatment with tulobuterol increases isometric contractile properties of diaphragm muscle in mice.
Shindoh C; Tsushima R; Shindoh Y; Tamura G
Tohoku J Exp Med; 2007 Jul; 212(3):309-17. PubMed ID: 17592218
[TBL] [Abstract][Full Text] [Related]
2. Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis.
Shindoh C; Murakami Y; Shishido R; Sasaki K; Nishio T; Miura M
Tohoku J Exp Med; 2009 Aug; 218(4):271-8. PubMed ID: 19638730
[TBL] [Abstract][Full Text] [Related]
3. Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice.
Shindoh C; Sasaki K; Shindoh Y; Tamura G
Allergol Int; 2007 Sep; 56(3):285-91. PubMed ID: 17646734
[TBL] [Abstract][Full Text] [Related]
4. Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy.
Burioka N; Miyata M; Endo M; Fukuoka Y; Suyama H; Nakazaki H; Igawa K; Shimizu E
Chronobiol Int; 2005; 22(2):383-90. PubMed ID: 16021849
[TBL] [Abstract][Full Text] [Related]
5. Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function.
Kume H; Kondo M; Ito Y; Suzuki R; Yamaki K; Takagi K
Clin Exp Pharmacol Physiol; 2002 Dec; 29(12):1076-83. PubMed ID: 12390295
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity].
Horiguchi T; Kondo R; Miyazaki J; Torigoe H; Tachikawa S
Nihon Kokyuki Gakkai Zasshi; 2004 Feb; 42(2):132-7. PubMed ID: 15007912
[TBL] [Abstract][Full Text] [Related]
7. Skin permeability of tulobuterol in two transdermal formulations and their followability.
Takizawa Y; Goto T; Sato S; Ohmori N; Mori K; Shimada Y; Chen K; Miyagi T; Fukai F
Drug Discov Ther; 2017 Nov; 11(5):253-258. PubMed ID: 29021505
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation.
Uematsu T; Nakano M; Kosuge K; Kanamaru M; Nakashima M
Eur J Clin Pharmacol; 1993; 44(4):361-4. PubMed ID: 8099880
[TBL] [Abstract][Full Text] [Related]
9. [Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].
Kato H; Nagata O; Yamazaki M; Suzuki T; Nakano Y
Yakugaku Zasshi; 2002 Jan; 122(1):57-69. PubMed ID: 11828751
[TBL] [Abstract][Full Text] [Related]
10. Effects of transdermal tulobuterol in pediatric asthma patients on long-term leukotriene receptor antagonist therapy: results of a randomized, open-label, multicenter clinical trial in Japanese children aged 4-12 years.
Katsunuma T; Fujisawa T; Nagao M; Akasawa A; Nomura I; Yamaoka A; Kondo H; Masuda K; Yamaguchi K; Terada A; Ikeda M; Nishioka K; Adachi Y; Kurihara K
Allergol Int; 2013 Mar; 62(1):37-43. PubMed ID: 23000726
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological effects mediated by the stimulation of cardiac beta 2-adrenoceptors with tulobuterol.
Mugelli A; Amerini S; De Bonfioli Cavalcabo P; Cerbai E; Visentin S
Cardiovasc Drugs Ther; 1987; 1(1):101-7. PubMed ID: 2908698
[TBL] [Abstract][Full Text] [Related]
12. Beta-agonistic properties of tulobuterol, a new beta-sympathicomimetic drug, and its effects on pulmonary beta-adrenoceptor characteristics.
Terpstra GK; Raaijmakers JA
Lung; 1990; 168 Suppl():179-85. PubMed ID: 1974673
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists.
Yamagata T; Hirano T; Sugiura H; Yanagisawa S; Ichikawa T; Ueshima K; Akamatsu K; Nakanishi M; Matsunaga K; Minakata Y; Ichinose M
Pulm Pharmacol Ther; 2008; 21(1):160-5. PubMed ID: 17632023
[TBL] [Abstract][Full Text] [Related]
14. Treatment with beta2-adrenoceptor agonist in vivo induces human clock gene, Per1, mRNA expression in peripheral blood.
Burioka N; Takata M; Endo M; Miyata M; Takeda K; Chikumi H; Tomita K; Fukuoka Y; Nakazaki H; Sano H; Shimizu E
Chronobiol Int; 2007; 24(1):183-9. PubMed ID: 17364588
[TBL] [Abstract][Full Text] [Related]
15. Transdermal tulobuterol patch, a long-actingβ(2)-agonist.
Tamura G; Ichinose M; Fukuchi Y; Miyamoto T
Allergol Int; 2012 Jun; 61(2):219-29. PubMed ID: 22270072
[TBL] [Abstract][Full Text] [Related]
16. Direct inotropic effect of the beta-2 receptor agonist terbutaline on impaired diaphragmatic contractility in septic rats.
Uzuki M; Yamakage M; Fujimura N; Namiki A
Heart Lung; 2007; 36(2):140-7. PubMed ID: 17362795
[TBL] [Abstract][Full Text] [Related]
17. Beta-2 adrenergic responses to tulobuterol in airway smooth muscle, vascular smooth muscle and adrenergic nerves.
Ruff F; Zander JF; Edoute Y; Santais MC; Flavahan NA; Verbeuren TJ; Vanhoutte PM
J Pharmacol Exp Ther; 1988 Jan; 244(1):173-80. PubMed ID: 2826765
[TBL] [Abstract][Full Text] [Related]
18. The effects of beta 2-agonists and caffeine on respiratory and limb muscle performance.
Lanigan C; Howes TQ; Borzone G; Vianna LG; Moxham J
Eur Respir J; 1993 Sep; 6(8):1192-6. PubMed ID: 7901049
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma.
Horiguchi T; Kondo R; Miyazaki J; Fukumokto K; Torigoe H
Arzneimittelforschung; 2004; 54(5):280-5. PubMed ID: 15212190
[TBL] [Abstract][Full Text] [Related]
20. Characterization of monolithic matrix patch system containing tulobuterol.
Rhee YS; Kwon SY; Park CW; Choi NY; Byun WJ; Chi SC; Park ES
Arch Pharm Res; 2008 Aug; 31(8):1029-34. PubMed ID: 18787793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
